Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.625
Bid: 1.60
Ask: 1.65
Change: 0.00 (0.00%)
Spread: 0.05 (3.125%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.625
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Change of Nomad and Adviser

28 Nov 2008 07:30

RNS Number : 1247J
EpiStem Holdings plc
28 November 2008
 



]

For Immediate Release

28 November 2008

Epistem Holdings plc

 

("Epistem" or "the Company")

Change of Adviser

Amendment to Articles of Association

and 

Notification re Schedule 2 paragraph (g) of the AIM Rules

Epistem (LSE: EHP), the UK biotechnology and contract research company, is pleased to announce the appointment with immediate effect of Piper Jaffray Ltd. as Nominated Adviser and sole broker to the Company. 

The Company announces that following the AGM held on 26th November 2008, the articles of association of the Company were amended by the insertion of the new following article 48:

"Subject always to the provisions of the Companies Act 2006, the board of directors of the Company from time to time may authorise any matter which would, if not so authorised, result in a director infringing his duty under section 175 of the Companies Act 2006 to avoid a situation in which he has, or can have a direct or indirect interest that conflicts or possibly may conflict with the interests of the Company."

All resolutions proposed at the AGM were duly passed.

The Company also announces that Mr. Matthew Walls, the Company's Chief Executive Officer, was previously a director of Zylepsis Limited ("Zylepsis") which went into administrative receivership on 3 October 2003. Mr. Walls gave notice of his resignation from Zylepsis on 10 April 2003 in order to pursue other career opportunities. Having worked an agreed period of notice, Mr. Walls ceased to be an employee of Zylepsis on 10 June 2003, at which date he also ceased to be a director of Zylepsis. The administrative receivership is still ongoing and Mr. Walls has not been the subject of any public criticism in connection with this event.

For further information please contact: 

Epistem

Matthew Walls, Chief Executive Officer

+44 (0) 161 606 7258

Piper Jaffray Ltd.

Neil Mackison / James Steel

+44 (0) 20 3142 8700

De Facto Communications

Anna Dunphy / Mike Wort

+ 44 (0) 20 7861 3838

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPDGMZMVNNGRZM
Date   Source Headline
13th Feb 20209:53 amRNSHolding(s) in Company
11th Feb 20204:00 pmRNSDirector/PDMR Shareholding
6th Feb 20204:30 pmRNSHolding(s) in Company
5th Feb 20205:38 pmRNSDirector/PDMR Shareholding
5th Feb 20205:32 pmRNSDirector/PDMR Shareholding
5th Feb 20204:45 pmRNSHolding(s) in Company
5th Feb 20207:15 amEQSHardman & Co Research: genedrive plc (GDR): Western market progress but developing markets difficult
4th Feb 20204:25 pmRNSDirector/PDMR Shareholding
4th Feb 20202:06 pmRNSSecond Price Monitoring Extn
4th Feb 20202:00 pmRNSPrice Monitoring Extension
4th Feb 20207:00 amRNSHalf-year Report
15th Jan 20207:00 amRNSNotice of Results
11th Dec 20195:24 pmRNSHolding(s) in Company
11th Dec 201910:06 amRNSHolding(s) in Company
5th Dec 201911:30 amRNSAdditional Listing
3rd Dec 20197:00 amRNSAIHL assay kit demonstrates high clinical accuracy
27th Nov 20194:23 pmRNSResult of AGM
22nd Nov 20192:41 pmRNSDirector/PDMR Shareholding
21st Nov 201912:30 pmEQSHardman & Co Research: genedrive plc (GDR): Regulatory hurdle leaped: hearing loss assay
18th Nov 20197:00 amRNSAntibiotic Induced Hearing Loss Assay CE marking
6th Nov 20197:00 amRNSNotice of AGM and Change of Auditors
28th Oct 20197:30 amEQSHardman & Co Research: genedrive plc (GDR): Acceleration of news flow expected
22nd Oct 20193:07 pmRNSHolding(s) in Company
22nd Oct 20193:06 pmRNSHolding(s) in Company
7th Oct 20197:00 amRNSNHS Ethics approval for use of AIHL test in trials
3rd Oct 20197:00 amRNSFinal Results
9th Sep 20197:00 amRNSNotice of Results
18th Jul 20197:30 amEQSHardman & Co Research: genedrive plc (GDR): Hepatitis C market frustrations
18th Jul 20197:00 amRNSDirector/PDMR Shareholding
9th Jul 20197:00 amRNSTrading Update
8th Apr 201910:54 amEQSHardman & Co Research: genedrive plc (GDR): First commercial sales in new focus area: bio-threats
5th Apr 20198:29 amRNSDirector/PDMR Shareholding
28th Mar 20197:00 amRNSHalf-year Report
16th Jan 20191:21 pmRNSHolding(s) in Company
15th Jan 20197:00 amRNSTrading update
31st Dec 201811:30 amRNSResult of AGM
12th Dec 20187:49 amRNSHolding(s) in Company
11th Dec 20187:15 amEQSHardman & Co Research: genedrive plc (GDR): Accelerating into fiscal 2019 with first sales
10th Dec 20184:44 pmRNSHolding(s) in Company
10th Dec 20183:40 pmRNSHolding(s) in Company
10th Dec 201811:04 amRNSHolding(s) in Company
7th Dec 20183:07 pmRNS2018 Annual Report and AGM Notice
7th Dec 20182:59 pmRNSResult of GM
29th Nov 20187:00 amRNSAbbVie to use HCV assay in study
19th Nov 20183:27 pmRNSPosting of Shareholder Circular
16th Nov 20181:42 pmRNSResult of Equity Placing
16th Nov 20187:00 amRNSProposed Placing and Broker Option
16th Nov 20187:00 amRNSUnaudited Preliminary Results
10th Sep 20181:46 pmRNSDirector/PDMR Shareholding
24th Aug 20187:00 amRNSNotice of GM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.